Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.13−0.24 (-3.26%)
Close on Nov 17, 2026Market cap $382.38MP/E –Yield –
Avalo Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Avalo Therapeutics's total assets was $490.78M at Jun 30, 2026. For fiscal 2025 it was $116.46M, down 22.7% from the year before. Over ten years it grew 18.3% a year on average. The highest annual figure on record is $150.73M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.46M | -22.7% |
| FY2024 | Dec 31, 2024 | $150.73M | +618.0% |
| FY2023 | Dec 31, 2023 | $20.99M | -37.1% |
| FY2022 | Dec 31, 2022 | $33.37M | -58.4% |
| FY2021 | Dec 31, 2021 | $80.21M | +83.3% |
| FY2020 | Dec 31, 2020 | $43.76M | +21.2% |
| FY2019 | Dec 31, 2019 | $36.11M | -48.6% |
| FY2018 | Dec 31, 2018 | $70.25M | +64.1% |
| FY2017 | Dec 31, 2017 | $42.81M | +642.0% |
| FY2016 | Dec 31, 2016 | $5.77M | -73.4% |
| FY2015 | Dec 31, 2015 | $21.66M | +75.8% |
| FY2014 | Dec 31, 2014 | $12.32M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $490.78M | +287.7% |
| Q1 FY2026 | Mar 31, 2026 | $99.89M | -27.9% |
| Q4 FY2025 | Dec 31, 2025 | $116.46M | -22.7% |
| Q3 FY2025 | Sep 30, 2025 | $125.10M | +27.1% |
| Q2 FY2025 | Jun 30, 2025 | $126.58M | +16.9% |
| Q1 FY2025 | Mar 31, 2025 | $138.52M | +12.0% |
| Q4 FY2024 | Dec 31, 2024 | $150.73M | +618.0% |
| Q3 FY2024 | Sep 30, 2024 | $98.46M | +236.4% |
| Q2 FY2024 | Jun 30, 2024 | $108.31M | +346.9% |
| Q1 FY2024 | Mar 31, 2024 | $123.73M | +241.5% |
| Q4 FY2023 | Dec 31, 2023 | $20.99M | -37.1% |
| Q3 FY2023 | Sep 30, 2023 | $29.27M | -19.9% |
| Q2 FY2023 | Jun 30, 2023 | $24.24M | -24.8% |
| Q1 FY2023 | Mar 31, 2023 | $36.24M | -41.5% |
| Q4 FY2022 | Dec 31, 2022 | $33.37M | -58.4% |
| Q3 FY2022 | Sep 30, 2022 | $36.55M | -61.7% |
| Q2 FY2022 | Jun 30, 2022 | $32.22M | -49.7% |
| Q1 FY2022 | Mar 31, 2022 | $61.90M | -2.3% |
| Q4 FY2021 | Dec 31, 2021 | $80.21M | +83.3% |
| Q3 FY2021 | Sep 30, 2021 | $95.36M | +61.1% |
| Q2 FY2021 | Jun 30, 2021 | $64.09M | -7.4% |
| Q1 FY2021 | Mar 31, 2021 | $63.35M | +43.6% |
| Q4 FY2020 | Dec 31, 2020 | $43.76M | +21.2% |
| Q3 FY2020 | Sep 30, 2020 | $59.19M | +3.5% |
| Q2 FY2020 | Jun 30, 2020 | $69.20M | +16.1% |
| Q1 FY2020 | Mar 31, 2020 | $44.12M | -41.1% |
| Q4 FY2019 | Dec 31, 2019 | $36.11M | -48.6% |
| Q3 FY2019 | Sep 30, 2019 | $57.19M | -15.4% |
| Q2 FY2019 | Jun 30, 2019 | $59.62M | -4.1% |
| Q1 FY2019 | Mar 31, 2019 | $74.87M | +14.5% |
| Q4 FY2018 | Dec 31, 2018 | $70.25M | +64.1% |
| Q3 FY2018 | Sep 30, 2018 | $67.61M | +139.7% |
| Q2 FY2018 | Jun 30, 2018 | $62.15M | +927.6% |
| Q1 FY2018 | Mar 31, 2018 | $65.36M | +1735.6% |
| Q4 FY2017 | Dec 31, 2017 | $42.81M | +642.0% |
| Q3 FY2017 | Sep 30, 2017 | $28.20M | +194.3% |
| Q2 FY2017 | Jun 30, 2017 | $6.05M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.56M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.77M | – |
| Q3 FY2016 | Sep 30, 2016 | $9.58M | – |
See a number that looks wrong?